{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:30:58Z","timestamp":1784212258907,"version":"3.55.0"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The cause of autoimmune diseases remains incompletely understood. Here, we highlight recent advances in the role of proinflammatory metabolic pathways in autoimmune disease, including treatment with antioxidants and mechanistic target of rapamycin (mTOR) inhibitors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent studies show that mTOR pathway activation, glucose utilization, mitochondrial oxidative phosphorylation, and antioxidant defenses play critical roles in the pathogenesis of autoimmune diseases, including rheumatoid arthritis, immune thrombocytopenia, Sj\u00f6gren's syndrome, large vessel vasculitis, and systemic lupus erythematosus. mTOR activity leads to Th1 and Th17 cell proliferation, Treg depletion, plasma cell differentiation, macrophage dysfunction, and increased antibody and immune complex production, ultimately resulting in tissue inflammation. mTOR also affects the function of connective tissue cells, including fibroblast-like synoviocytes, endothelial cells, and podocytes. mTOR inhibition via rapamycin and N-acetylcysteine, and blockade of glucose utilization show clinical efficacy in both mouse models and clinical trials, such as systemic lupus erythematosus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The mTOR pathway is a central regulator of growth and survival signals, integrating environmental cues to control cell proliferation and differentiation. Activation of mTOR underlies inflammatory lineage specification, and mTOR blockade-based therapies show promising efficacy in several autoimmune diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000687","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T20:47:24Z","timestamp":1577825244000},"page":"184-191","source":"Crossref","is-referenced-by-count":36,"title":["Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases"],"prefix":"10.1097","volume":"32","author":[{"given":"Brandon","family":"Wyman","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine"},{"name":"Department of Biochemistry and Molecular Biology, State University of New York, Upstate Medical University, College of Medicine, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Perl","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine"},{"name":"Department of Microbiology and Immunology"},{"name":"Department of Biochemistry and Molecular Biology, State University of New York, Upstate Medical University, College of Medicine, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1139\/y77-007","article-title":"Inhibition of the immune response by rapamycin, a new antifungal antibiotic","volume":"55","author":"Martel","year":"1977","journal-title":"Can J Physiol Pharmacol"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J Biol Chem"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1749-6632.1993.tb35855.x","article-title":"Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases","volume":"685","author":"Carlson","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/art.1780370219","article-title":"Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus","volume":"37","author":"Warner","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4049\/jimmunol.154.2.922","article-title":"Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis","volume":"154","author":"Martin","year":"1995","journal-title":"J Immunol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2010.09.002","article-title":"The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism","volume":"33","author":"Powell","year":"2010","journal-title":"Immunity"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ceb.2011.08.006","article-title":"TOR in the immune system","volume":"23","author":"Araki","year":"2011","journal-title":"Curr Opin Cell Biol"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12756","article-title":"mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging","volume":"1346","author":"Perl","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ni.2005","article-title":"The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2","volume":"12","author":"Delgoffe","year":"2011","journal-title":"Nat Immunol"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.it.2018.04.006","article-title":"Metabolism as a target for modulation in autoimmune diseases","volume":"39","author":"Huang","year":"2018","journal-title":"Trends Immunol"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.celrep.2012.02.007","article-title":"PI3K-Akt-mTORC1-S6K1\/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORgamma","volume":"1","author":"Kurebayashi","year":"2012","journal-title":"Cell Rep"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1007\/s00018-015-1976-1","article-title":"Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1\/2 signaling pathway in normal and neoplastic B-lymphoid cells","volume":"72","author":"Zeng","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/jcp.25913","article-title":"Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1\/2 signaling in normal and neoplastic B-lymphoid cells","volume":"233","author":"Zeng","year":"2018","journal-title":"J Cell Physiol"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imm.12126","article-title":"Rapamycin unbalances the polarization of human macrophages to M1","volume":"140","author":"Mercalli","year":"2013","journal-title":"Immunology"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaut.2012.05.021","article-title":"Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction","volume":"39","author":"Boissier","year":"2012","journal-title":"J Autoimmun"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/ard.2007.078808","article-title":"Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study","volume":"67","author":"Bruyn","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1084\/jem.20130252","article-title":"Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells","volume":"210","author":"Yang","year":"2013","journal-title":"J Exp Med"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.celrep.2018.04.044","article-title":"mTOR senses environmental cues to shape the fibroblast-like synoviocyte response to inflammation","volume":"23","author":"Karonitsch","year":"2018","journal-title":"Cell Rep"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/intimm\/dxr077","article-title":"IL-1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis","volume":"23","author":"Mori","year":"2011","journal-title":"Int Immunol"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"10965","DOI":"10.1038\/s41598-017-11233-w","article-title":"Stat3 as a potential therapeutic target for rheumatoid arthritis","volume":"7","author":"Oike","year":"2017","journal-title":"Sci Rep"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Zhou","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"e50909","DOI":"10.1371\/journal.pone.0050909","article-title":"The ratio of Treg\/Th17 cells correlates with the disease activity of primary immune thrombocytopenia","volume":"7","author":"Ji","year":"2012","journal-title":"PLoS One"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"e0142634","DOI":"10.1371\/journal.pone.0142634","article-title":"Indirubin increases CD4+CD25+Foxp3+ regulatory T cells to prevent immune thrombocytopenia in mice","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/jcmm.14089","article-title":"Indirubin modulates CD4(+) T-cell homeostasis via PD1\/PTEN\/AKT signalling pathway in immune thrombocytopenia","volume":"23","author":"Zhao","year":"2019","journal-title":"J Cell Mol Med"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"548085","DOI":"10.1155\/2013\/548085","article-title":"Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia","volume":"2013","author":"Li","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MPH.0000000000000818","article-title":"Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans syndrome (ES): a single institution's experience","volume":"39","author":"Jasinski","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12935-019-0779-0","article-title":"Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy","volume":"19","author":"Sun","year":"2019","journal-title":"Cancer Cell Int"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.exphem.2015.01.001","article-title":"Loss of autophagy leads to failure in megakaryopoiesis, megakaryocyte differentiation, and thrombopoiesis in mice","volume":"43","author":"Cao","year":"2015","journal-title":"Exp Hematol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2014-09-598722","article-title":"Autophagy is induced upon platelet activation and is essential for hemostasis and thrombosis","volume":"126","author":"Ouseph","year":"2015","journal-title":"Blood"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2005-07-3005","article-title":"Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation","volume":"107","author":"Raslova","year":"2006","journal-title":"Blood"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/stemcells.2005-0062","article-title":"Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors","volume":"24","author":"Drayer","year":"2006","journal-title":"Stem Cells"},{"key":"R41-20230828","first-page":"4016","article-title":"Immune thrombocytopenia induces autophagy and suppresses apoptosis in megakaryocytes","volume":"18","author":"Liu","year":"2018","journal-title":"Mol Med Rep"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2016.01.011","article-title":"Targeting autophagy as a potential therapeutic approach for immune thrombocytopenia therapy","volume":"100","author":"Shan","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","article-title":"Clinical manifestations and early diagnosis of Sjogren syndrome","volume":"164","author":"Kassan","year":"2004","journal-title":"Arch Intern Med"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2013.07.016","article-title":"A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjogren's syndrome","volume":"171","author":"Shah","year":"2013","journal-title":"J Control Release"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"e000701","DOI":"10.1136\/rmdopen-2018-000701","article-title":"Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjogren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?","volume":"5","author":"Blokland","year":"2019","journal-title":"RMD Open"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key017","article-title":"mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G","volume":"57","author":"Hadjadj","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2018.07.013","article-title":"mTOR pathway activation in large vessel vasculitis","volume":"94","author":"Maciejewski-Duval","year":"2018","journal-title":"J Autoimmun"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1517\/14656560902971003","article-title":"Pharmacotherapy of systemic lupus erythematosus","volume":"10","author":"Francis","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.4049\/jimmunol.0803600","article-title":"Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1\/Rab4-regulated lysosomal degradation","volume":"182","author":"Fernandez","year":"2009","journal-title":"J Immunol"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.22085","article-title":"Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/art.40380","article-title":"Blockade of Treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus","volume":"70","author":"Kato","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/art.41019","article-title":"Glutaminase 1 inhibition reduces glycolysis and ameliorates lupus-like disease in MRL\/lpr mice and experimental autoimmune encephalomyelitis","volume":"71","author":"Kono","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1172\/JCI127949","article-title":"Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity","volume":"129","author":"Katsuyama","year":"2019","journal-title":"J Clin Invest"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.4049\/jimmunol.1301859","article-title":"Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus","volume":"192","author":"Kato","year":"2014","journal-title":"J Immunol"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.1301005","article-title":"Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus","volume":"191","author":"Lai","year":"2013","journal-title":"J Immunol"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.immuni.2014.08.011","article-title":"The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production","volume":"41","author":"Kobayashi","year":"2014","journal-title":"Immunity"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-016-0989-y","article-title":"CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis","volume":"18","author":"Olmes","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/ndt\/gfn216","article-title":"Rapamycin attenuates the severity of established nephritis in lupus-prone NZB\/W F1 mice","volume":"23","author":"Lui","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2018-213028","article-title":"Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-alpha in lupus nephritis","volume":"77","author":"Qi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/art.39791","article-title":"Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice","volume":"68","author":"Oaks","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R64-20230828","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/0961203307081401","article-title":"Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment","volume":"16","author":"Ramos-Barron","year":"2007","journal-title":"Lupus"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/art.34502","article-title":"N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R67-20230828","doi-asserted-by":"crossref","first-page":"274ra18","DOI":"10.1126\/scitranslmed.aaa0835","article-title":"Normalization of CD4+ T cell metabolism reverses lupus","volume":"7","author":"Yin","year":"2015","journal-title":"Sci Transl Med"},{"key":"R68-20230828","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/art.30395","article-title":"Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis","volume":"63","author":"Biniecka","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R69-20230828","doi-asserted-by":"crossref","first-page":"e0127558","DOI":"10.1371\/journal.pone.0127558","article-title":"Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N-acetylcysteine and N-acetylcysteine amide","volume":"10","author":"Paul","year":"2015","journal-title":"PLoS One"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/annrheumdis-2014-205743","article-title":"PPARgamma deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage","volume":"74","author":"Vasheghani","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R71-20230828","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2013-204599","article-title":"Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis","volume":"74","author":"Zhang","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI119382","article-title":"Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells","volume":"99","author":"Javier","year":"1997","journal-title":"J Clin Invest"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.27498","article-title":"Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis","volume":"62","author":"Yoshizaki","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R74-20230828","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/art.24986","article-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study","volume":"60","author":"Su","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R75-20230828","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1086\/674311","article-title":"Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial","volume":"3","author":"Seyfarth","year":"2013","journal-title":"Pulm Circ"},{"key":"R76-20230828","first-page":"253","article-title":"A double-blind, cross-over, study of oral N-acetylcysteine in Sjogren's syndrome","volume":"61","author":"Walters","year":"1986","journal-title":"Scand J Rheumatol Suppl"},{"key":"R77-20230828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multiinstitutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:16:40Z","timestamp":1693199800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000687","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}